Abstract
Abstract
Purpose
Colistin is used as a last resort antibiotic against infections caused by multidrug-resistant gram-negative bacteria, especially carbapenem-resistant bacteria. However, colistin-resistance in clinical isolates is becoming more prevalent. Cinnamaldehyde and baicalin, which are the major active constituents of Cinnamomum and Scutellaria, have been reported to exhibit antibacterial properties. The aim of this study was to evaluate the capacity of cinnamaldehyde and baicalin to enhance the antibiotic activity of colistin in Enterobacterales and Acinetobacter baumannii strains.
Methods
The MICs of colistin were determined with and without fixed concentrations of cinnamaldehyde and baicalin by the broth microdilution method. The FIC indices were also calculated. In addition, time-kill assays were performed with colistin alone and in combination with cinnamaldehyde and baicalin to determine the bactericidal action of the combinations. Similarly, the effects of L-arginine, L-glutamic acid and sucrose on the MICs of colistin combined with cinnamaldehyde and baicalin were studied to evaluate the possible effects of these compounds on the charge of the bacterial cell- wall.
Results
At nontoxic concentrations, cinnamaldehyde and baicalin partially or fully reversed resistance to colistin in Enterobacterales and A. baumannii. The combinations of the two compounds with colistin had bactericidal or synergistic effects on the most resistant strains. The ability of these agents to reverse colistin resistance could be associated with bacterial cell wall damage and increased permeability.
Conclusion
Cinnamaldehyde and baicalin are good adjuvants for the antibiotic colistin against Enterobacterales- and A. baumannii-resistant strains.
Funder
Ministerio de Educación, Cultura y Deporte
Universidad de las Palmas de Gran Canaria
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. World Health Organization (2017a) WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 27 Feb 2017
2. Mancuso G, Midiri A, Gerace E, Biondo C (2021) Bacterial antibiotic resistance: the most critical pathogens. Pathogens 10:1310. https://doi.org/10.3390/pathogens10101310
3. World Health Organization (2017b) Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. Accessed 4 Sept 2017. https://www.who.int/publications/i/item/WHO-EMP-IAU-2017.12
4. El Chakhtoura NG, Saade E, Iovleva A, Yasmin M, Perez F, Bonomo RA (2018) Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy. Expert Rev Anti Infect Ther 16:89–110. https://doi.org/10.1080/14787210.2018.1425139
5. El-Sayed Ahmed MAEG, Zhong LL, Shen C, Yang Y, Doi Y, Tian G-B (2020) Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019). Emerg Microbes Infect 9:868–885. https://doi.org/10.1080/22221751.2020.1754133